Thr74

Site Information
sPCIIIEtPHKEIGT SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 5996402

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 ) , mutation of modification site ( 6 ) , western blotting ( 6 )
Disease tissue studied:	breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 2 )
Relevant cell line - cell type - tissue:	breast ( 1 , 2 ) , HEK293T (epithelial) ( 6 ) , Jurkat (T lymphocyte) ( 3 , 4 , 5 )

Downstream Regulation
Effects of modification on CCNE2:	protein degradation ( 6 ) , ubiquitination ( 6 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
3	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
4	Guo A (2011) CST Curation Set: 12435; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
5	Guo A (2011) CST Curation Set: 12436; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
6	Klotz K, et al. (2009) SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis. Exp Cell Res 315, 1832-9 19084516 Curated Info